NEED HELP?


Name:
Phone
Email:
 


 

Anton J. Bilchik, M.D., Ph.D., F.A.C.S.


Medical Director, California Oncology Research Institute

Dr. Bilchik is Co-Founder and Medical Director for the California Oncology Research Institute (CORI). Internationally recognized for his research in surgical oncology and gastrointestinal malignancies, Dr. Bilchik directs and manages the treatment and research of all gastrointestinal cancers at CORI. As a leader in gastrointestinal research, he has pioneered a novel surgical approach for the laparoscopic staging of colon cancer, along with minimally invasive approaches for the destruction of liver tumors. Drawing from his surgical innovations, he focuses his scientific research to include molecular profiling, the staging of gastrointestinal cancers, and immunotherapy. Dr. Bilchik is concentrating on providing a multidisciplinary approach with scientific research to improve the understanding of cancer, while individualizing therapy for all of his patients using both novel surgical and scientific methods. 

 

Prior to co-founding CORI, Dr. Bilchik served as the Director of the Gastrointestinal Research Program at the John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California. As a member of the faculty, he was responsible for training and mentoring fellows participating in JWCI’s prestigious fellowship program for surgical oncology. While at JWCI, Dr. Bilchik published more than 170 peer review journals and editorials, and was invited globally to lecture, present, and participate in various consensus panels in cancer research.

 

In addition to his distinguished career at JWCI, Dr. Bilchik has received numerous awards and accolades. He has been honored by the American Cancer Society, the University of Leiden, and is listed as one of “Americas Top Doctors.” Dr. Bilchik is also the recipient of numerous grants for cancer research, including the National Cancer Institute for colon cancer. He is an active member for the editorial board of four cancer journals, participates on the executive council for two, leading national medical societies, and was asked to join the National Cancer Institute study section that awards clinical trial grants in research. Most recently, Dr. Bilchik was elected to the American Surgical Association, the most prestigious surgical society in the United States.

 

He received his medical degree from the University of Witwatersrand in South Africa, and completed his PhD in gastrointestinal physiology at Yale University. He performed residency in general surgery at UCLA, where he received the Golden Apple award for teaching excellence, and where he retains an appointment. Before serving as a faculty member at JWCI, Dr. Bilchik completed JWCI’s surgical oncology fellowship training program.
ANTON J. BILCHIK, M.D., Ph.D., FACS
Work Address:  

California Oncology Research Institute
2336 Santa Monica Boulevard #206
Santa Monica, California 90404
Tel: (310) 696-0716
Fax: (310) 696-0724
Email: abilchik@aol.com or abilchik@mednet.ucla.edu

                                   
Marital Status:   Married, 2 children
Present Position:  

Medical Director, California Oncology Research Institute

Professor, David Geffen School of Medicine at UCLA

Education:    
1980-1983   Undergraduate: University of Witwatersrand
1980-1985   Medical School: University of Witwatersrand School of Medicine, Johannesburg, SA
1986   Rotating internship: Johannesburg General, Johannesburg
1987-1990   Ph.D./Postdoctoral Associate: GI Surgical Research Group: Yale University School of Medicine, CT
1990-1991   Surgical Internship: University of California, Los Angeles
1992-1993   Surgical Research Fellow: University of California, Los Angeles
1991-1996   General Surgery Residency: University of California, Los Angeles (M.J. Zinner)
1996   Chief Resident: University of California, Los Angeles, CA
1996-1997   Surgical Oncology Fellowship: John Wayne Cancer Institute (D.L. Morton)
Degrees:    
1985   MBBcH
1991   PhD Growth and secretory effects of cholecystokinin and its permissive role in experimental pancreatitis.
Licensure:    
1987   United States   FMGEMS/ECFMG No.3985454
1988   United States   FLEX ID 620927500
1987   Britain   No.3162691 (Registered with British Medical Council)
1987   South Africa   No.IN 19467 S.A.M.D.C
1991   California   A49766
1991   DEA   BB2950980
Board Certification:    
1996   Board certified, General Surgery 052475
Academic Appointments:
1996-Present   Assistant Clinical Professor, UCLA School of Medicine
1997-2003   Assistant Director of Surgical Oncology, John Wayne Cancer Institute
2003-2007   Director Gastrointestinal Surgical Oncology, John Wayne Cancer Institute Associate Director of Surgical Oncology, John Wayne Cancer Institute
2008-present   Medical Director, California Oncology Research Institute Professor, David Geffen School of Medicine at UCLA
Hospital Appointments:
1996-Present   Saint John’s Hospital and Health Center, Santa Monica, CA
1996-2004   Century City Medical Center, Los Angeles, CA
2004-2007   Midway Hospital Medical Center, Los Angeles, CA
2004-Present   Cedars-Sinai Medical Center, Los Angeles, CA
Professional Honors or Awards:
1985   Black Belt, 2nd Degree
1987   Gold Medal awarded at National University Championships Appointed Karate Instructor, Yale University
1988   First prize presentation, Connecticut Chapter, American College of Surgeons
1989   Black Belt, 3rd Degree
1990   Winner, Publication of the Year Surgical Research Communications
1992   Finalist, American College of Surgeons, Research Fellowship
1992   Finalist, Association Academic Surgeons, Research Fellowship
1996   

Golden Apple Award “Outstanding Teacher”
UCLA General Surgery

1999  

Vice Chair of Surgery, St. John’s Hospital

2000   Chief of Credential Committee, St. John’s Hospital
2000   Boerhaave Visiting Professor, University of Leiden
2001  

America’s Top Doctor – Surgery

2001       Chief of Surgery, Century City Hospital
2002   Young Surgeon Representative, American College of Surgeons
2002   America’s Top Doctor – Surgery
2003  

America’s Top Doctor – Surgery

2004      

America’s Top Doctor – Surgery

2005      

America’s Top Doctor – Surgery

2007      

Chief of Surgery, Century City Hospital

2010       America’s Top Doctor For Cancer For Five Years
2011   Jeffrey Kavolius Memorial Lecture in Surgical Oncology Gary Wratten Surgical Symposium, Augusta Georgia
Professional Organizations:
1998   

Member, Society Surgical Oncology

1998     Member, Longmire Surgical Society
1999     Member, Bay Surgical Society
1999     Fellow, American College of Surgeons
1999     Member, American Society of Clinical Oncology
2000   Member, Society of American Gastrointestinal Endoscopic Surgeons
2000   Member, American Gastroenterological Association
2000   Member, Western Surgical Association
2000   Member, Los Angeles Surgical Society
2000   Member, Southern California Chapter American College of Surgeons
2002  

Member, Pacific Coast Surgical Society

2002      

Local Program Chairman, Society of Surgical Oncology

2004   Member, Surgical Biology Club II
2006   Member of American Hepato Pancreato Biliary Association
2006   Program Committee, Western Surgical Association
2007   Member of American Surgical Association
2008      

Program committee, American Hepatobiliary Association

Executive Councils/Board of Directors:
2003-2007  

Western Surgical Association

2003-2007  

Society of Surgical Oncology

2010-2013           Board of Directors, Southern California Chapter American College of Surgeons
Editorial Boards:    
2000  

Ad hoc Reviewer, Cancer

2001      

Editorial Board, Annals of Surgical Oncology

2002   Editorial Board, Integrative Cancer Therapies
2002       Ad hoc Reviewer, Cancer
2003   Ad hoc Reviewer, Annals of Surgery
2004       Editorial Board, Journal of Clinical Oncology
2004       Editorial Board, Journal of Surgical Oncology
2004      

Ad hoc Reviewer, Journal of American College of Surgeons

2004   Ad hoc Reviewer, Surgery
2006   Ad hoc Reviewer, European Journal of Surgical Oncology
2007   Ad hoc Reviewer, Gastroenterology and Hepatology
2007   Ad hoc Reviewer, Diseases of Colon and Rectum
2007      

Ad hoc Reviewer, World Journal of Surgery

2008   Editorial Board, Journal of Interventional Oncology
NCI Grant Committees
2007  

Study Section “H” Review of Cancer Cooperative Groups and Grants

Clinical Areas of Special Interest:
    Gastrointestinal and Laparoscopic Surgery
   

Surgical Oncology

    Hepatic Malignancies
   

Ultrastaging of Gastrointestinal Malignancies

Research Areas of Special Interest:
    Physiology of circulating gastrointestinal regulatory peptides.
   

Radioimmunoassay of peptides in pathophysiological conditions.

   

Role of cholecystokinin in the control of growth and regulation of the pancreas.

   

Pathophysiology of an endocrine tumor-peptic ulcer model.

    Oncogene expression and amplification in carcinoid tumors.
   

Molecular and physiological regulation of small bowel absorption.

   

Molecular profiling of gastrointestinal malignancies.

   

Immunotherapy of gastrointestinal malignancies.

Research Grant Funding:

 

1988-1989  

Amelioration of traumatic pancreatitis by CCK antagonist.
OHSE research award-Yale University. $10,000, PI – AJ Bilchik M.D.

1989-1990  

Bacterial and specific contribution to the mortality of post traumatic pancreatitis
in a guinea pig model.
OHSE research award-Yale University. $9,500, PI – AJ Bilchik M.D

1990-1991  

Oncogene expression in mastomys carcinoid tumors.  OHSE research fund award-Yale University. $10,000, PI – AJ Bilchik M.D

1991-1997  

Surgery and intestinal absorption.
NIH DK39870-05. (Co-investigator) $600,000, PI – MJ Zinner

1997  

Early diagnosis and treatment of pancreatic cancer.
SPORE institutional grant (Collaborator)

1998  

Molecular Detection of Colon Cancer with a Multiple Marker PCR Assay.
  Rod Fasone Fund $10,000

1998-1999  

Rogavin-Davidow Foundation $75,000

1998-1999  

Polyvalent Vaccine: Phase III Trial in Stage IV Melanoma
NIH/NCI 5 P-01 CA29605-18  $878,746, PI – DL Morton M.D.

1998-1999  

New Approaches to Surgical Oncology
NIH/NCI 5 P01 CA 29605-18 $2,218,374, PI – DL Morton M.D.

1999  

Rod Fasone Fund $15,000

1999-2000  

Rogavin-Davidow Foundation $75,000

1999-2000  

Surgery, Immunology and Immunology of Human Cancer
NIH/NCI 5 P01 CA12582-28  $3,810,835, PI – DL Morton, M.D.

1999-2000  

Unrestricted research grant - Rita Medical Incorporated  $50,000

2000  

Rod Fasone Fund $10,000

2000-2003  

Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis $150,000, PI - AJ Bilchik M.D. Ph.D.

2000-2006  
  1.  Ultrastaging of Early Colon Cancer Using Lymphatic Mapping and Sentinel Node Analysis NIH/NCI 1 R01 CA90848-01  $2,631,076, PI – AJ Bilchik M.D. Ph.D.
2000-2005   Lymph node mapping and sentinel lymph node biopsy for stage I, II, III colon cancer.  American College of Surgeons Oncology Group Grant (submitted) Collaborator / Co-Investigator - AJ Bilchik M.D. Ph.D.
2000-2001  

Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer NIH/NCI K08 Grant (submitted), PI – AJ Bilchik M.D. Ph.D.

2000-2001  

Carbohydrate Antigens As Targets for Vaccine Immunotherapy in Colon Cancer American Cancer Society Beginning Investigators Grant (submitted), PI - AJ Bilchik M.D. Ph.D.

2000-2001  

Rogavin-Davidow Foundation $75,000

2001  

Polyvalent Vaccine: Phase III Trial in Stage IV Colon Cancer, PI – AJ Bilchik, M.D., Ph.D.

2001  

Rod Fasone Fund $15,000

2001  

George Hoag Foundation $35,000

2001-2002  

Rogavin-Davidow Foundation $75,000

2002  

SPORE in Pancreas Cancer, Co-Investigator – AJ Bilchik M.D. Ph.D., PI – T Adrian, Ph.D.

2002      

William Randolph Hearst Foundation $500,000

2002-2003  

Davidow Charitable Fund $75,000

2003-2004  

Davidow Charitable Fund $75,000

2004-2005  

Davidow Charitable Fund $75,000

2004-2006  

Davidow Charitable Fund $75,000

2009-2012  

William Randolph Hearst Foundation $150,000

2008-2012  

Ultrastaging of Early Colon Cancer. NIH/NCI 2RO1 CA90848-05A2 $2,638,184

PI – AJ Bilchik M.D.Ph.D. FUNDED

 

2010-2014   Molecular Profiling of Stage II Colon Cancer: US Military Cancer Institute Clinical Trials Group GI-02 $3,555,125 PI AJ Bilchik M.D.Ph.D. Submitted DOD
Original Publications:    
   
  1. Vellet D, Leiman G, Mair S, Bilchik AJ.  Fine needle aspiration cytology of mucinous cystadenocarcinoma of the pancreas: Further observations.  Acta Cytol 1988;32:43-48.
  2. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM. Deoxycholic acid release of peptide YY from colonic endocrine cells: a specific and non neurally mediated mechanism.  Surg Forum 1988;39:182-183.
  3. Basson MD, Fielding LP, Bilchik AJ, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM. Does VIP mediate the pathophysiology of bowel obstruction? Am J Surg 1989;157:109-115.
  4. Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM. Advanced rectal cancer: What Is the Best Palliation? Dis Colon Rectum 1989;31(11):842-847.
  5. Zucker KA, Longo WE, Bilchik AJ, Adrian TE, Modlin IM. Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 1989;84(2):182-186.
  6. Modlin IM, Bilchik AJ, Zucker KA, Adrian TE, Graham S, Sussman J. Cholecystokinin augmentation of surgical pancreatitis: Benefits of receptor blockade. Arch Surg 1989;124:574-578.
  7. Bilchik AJ, Modlin IM, Nilsson O, Zucker KA, Adrian TE. H2 receptor blockade induces peptide YY (PYY) and enteroglucagon (EG) secreting gastric carcinoids in mastomys. Surgery 1989;106(6):1119-1127.
  8. Zucker KA, Bilchik AJ, Adrian TE, Modlin IM. Postaglation E analogue inhibition of pancreatic enzyme secretion. Pancreas 1989;4(6):708-714.
  9. Ballantyne GH, Longo WE, Adrian TE, Vukasin A, Bilchik AJ, Modlin IM. Deoxycholate stimulated release of peptide YY from isolated perfused rabbit colon: a specific and non-neurally mediated mechanism. Am J Physiol 1989;257:G715-G724.
  10. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals. Am J Physiol 1989;257:G511-516.
  11. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM. cAMP mediated release of PYY from the isolated perfused colon: Evidence for negative feedback modulation of colonic secretion. Surg Forum 1989;40:177-180.
  12. Adrian TE, Zucker KA, Bilchik AJ, Modlin IM. A novel micro-method for pancreatic acinar secretion: Time course of CCK stimulation and its inhibition by L364,718. Int J Pancreatol 1990;6(1):61-69.
  13. Bilchik AJ, Zucker KA, Adrian TE, Sussman J, Modlin IM. Cholecystokinin receptor blockade ameliorates pancreatitis in a new surgical model. Surg Res Commun 1990;8(1):47-57.
  14. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA, Adrian TE. Significance of gastric endocrine tumor and age related gut peptide alterations in mastomys. Regul Peptides 1990;27(2):195-207.
  15. . Nillson O, Bilchik AJ, Adrian TE, Modlin IM. Intraocular transplantation of carcinoid tumors from mastomys and humans. J Pathol 1990;160(4):347-356.
  16. c
  17. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist. Arch Surg 1990;125(12):1546-1549.
  18. Bilchik AJ, Ballantyne GH, Modlin IM. Removal of malignant polyps is best done conservatively: A surgeon’s perspective. Debates Med 1990; Volume 3.
  19. Modlin IM, Bilchik AJ, Goldenring JR. Enterochromaffin-like cell tumor induction in mastomys by insurmountable H2 receptor blockade. Res Clin Forums 1990;12:59-80.
  20. Bilchik AJ, Leach SD, Zucker KA, Adrian TE, Modlin IM. Experimental models of acute pancreatitis. J Surg Res 1990;48(6):639-647.
  21. Longo We, Ballantyne GH, Adrian TE, Bilchik AJ, Modlin IM. Short chain fatty acid release of PYY in the isolated rabbit distal colon. Scand J Gastroenterol 1991;26:4424-4448.
  22. . Armstrong D, Ballantyne GH, Bilchik AJ, McMillen A, Adrian TE and Modlin IM. Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction. Dis Colon Rectum 1991;34(2):119-25.
  23. Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM. Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 1991;129(1):139-148.
  24. Modlin IM, Kim H, Bilchik AJ, Nilsson O, Esterline WJ, Goldenring JR. Pathobiology of enterochromaffin-like tumor induction in mastomys. The stomach as an endocrine organ. Eds. Hakanson R and Sundler F. Elsevier 1991;33:499-513.
  25. Vukasin AP, Ballantyne GH, Nilsson O, Bilchik AJ, Adrian TE, Modlin IM. Plasma and tissue alterations of peptide YY and enteroglucagon in rats after colectomy. Yale J Biol Med 1992;65(1):1-15.
  26. Leach SD, Bilchik AJ, Karapetian O, Gorelick FS, Modlin IM. Influence of choloroquine on diet-induced pancreatitis. Pancreas 1993;8(1):64-69.
  27. Bilchik AJ, Hines OJ, Adrian TE, Skotzko MJ, McFadden DW, Zinner MJ, Ashley SW. PYY gene expression is an early adaptive response to massive small bowel resection. Surg Forum 1993;44:126-128.
  28. Adrian TE, Ballantyne GH, Longo WE, Bilchik, AJ, Graham S, Basson MD, Tierney RP and Modlin IM. Deoxcholate is an important releaser of peptide YY and enteroglucagon from human colon. Gut 1993;34:198-206.
  29. Hines OJ, Bilchik AJ, Skotzko MJ, Zinner MJ, McFadden DW, Ashley SW. Translational control of meal-induced absorption. Surg Forum 1993;44:133-134.
  30. Herrington MK, Permert J, Kazakoff KR, Pour PM, Zucker KA, Bilchik AJ, Adiran TE. Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Carinogenesis 1993;14(5):1021-1026.
  31. Ballantyne GH, Goldenring JR, Bilchik AJ, Adrian TE, Modlin IM. cAMP-mediated release of peptide YY from the isolated perfused rabbit distal colon. Regul Peptides 1993;47:117-126.
  32. Bilchik AJ, Hines OJ, Adrian TE, McFadden DW, Berger JJ, Zinner MJ, Ashley SW. Peptide YY is the physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology 1993;105:1441-1448.
  33. Modlin IM, Lewis JJ, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993;176(5):507-518.
  34. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, Bereger JJ, Ashley SW, McFadden DW. Peptide YY augments postprandial small intestinal absorption in vivo. Am J Surgery 1994;167(6):570-574.
  35. . Hines OJ, Bilchik AJ, Zinner MJ, Skotzko MJ, McFadden DW, Ashley SW. Adaptation of the Na+/glucose cotransporter following intestinal resection. J Surg Res 1994;57(1):22-27.
  36. Herrington MK, Permert J, Kazakoff KR, Zucker KA, Bilchik AJ, Pour PM, Adrian TE. Effects of raw soya diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Cancer Letters 1994;82:7-16.
  37. Hines OJ, Bilchik AJ, McFadden DW, Zinner MJ, Ashley SW. Upregulation of the Na+/K+ ATPase following massive intestinal resection. Surgery 1994;116(2):401-408.
  38. Bilchik AJ, Hines OJ, Adrian TE, Ashley SW, Zinner MJ, McFadden DW. Peptide YY immunoneutralization inhibits meal induced absorption in vivo. Surgery 1994;116:1153-1158.
  39. Hines OJ, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW. Amino acids mediate postprandial jejunal postprandial absorption. J Surg Res 1995;58:81-85.
  40. Bilchik AJ, Hines OJ, Adrian TE, Zinner MJ, McFadden DW, Ashley SW. Early regional expression and secretion of peptide YY and enteroglucagon after massive small bowel resection. J Am Coll of Surg 1995;180:417-426
  41. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW. Na+/H+ exchange regulates postprandial ileal water and electrolyte absorption. Dig Dis Sci 1995;40:774-780.
  42. Liu CD, Aloia T, Adrian TE, Bilchik AJ, Ashley SW, Zinner MJ, McFadden DW. Peptide YY; a potential proabsorptive hormone for the treatment of malabsorptive disorders. Am Surg 1996;62(3):232-236.
  43. Whang EE, Hines OJ, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW. Antisecretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci 1997;42(6):1121-1127.
  44. Bilchik AJ, Sarantou T, Wardlow J, Ramming K. Cryosurgery causes a profound reduction in tumor markers in hepatoma and non-colorectal hepatic metastases. Am Surg 1997;63: 796-800.
  45. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano A, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040-1048.
  46. Sarantou T, Bilchik AJ, Ramming KP. Complications of hepatic cryosurgery. Semin Surg Oncol 1998;14:156-162.
  47. Bilchik AJ. Editorial Cryotherapy of liver tumors. Oncology July 1998.
  48. Bilchik AJ, Giuliano AE, Essner R, Bostick PJ, Kelemen P, Foshag LJ, Sostrin S, Turner RR, Morton DL. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998;4(6):351-358.
  49. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik AJ, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-541.
  50. Rose DM, Allegra DP, Bostick PJ, Foshag LJ, Bilchik AJ. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Am Surg 1999;65:1009-1014.
  51. Bilchik AJ, Rose DM, Bostick PJ, Chu K, Allegra D, Morton DL. Radiofrequency ablation – a minimally invasive technique with multiple applications. Cancer J Sci Am 1999;5(6):356-361.
  52. Bilchik AJ, Rose DM, Hsueh E, Foshag LJ, Morton DL. Cryosurgery and radiofrequency ablation of unresectable hepatic malignancies: A proposed algorithm. Arch Surg 2000;135(6):657-664.
  53. Hines OJ, Whang EE, Bilchik AJ, Zinner MJ, Welton M, Lane J, McFadden DE, Ashley SW. Role of Na+/-glucose co-transport in jejunal meal-induced absorption. Dig Dis Sci 2000;45:1-6.
  54. Bilchik AJ, Miyashiro M, Kelley M, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DSB. Molecular detection of metastatic pancreatic carcinoma cells using a multimarker RT-PCR assay. Cancer 2000;88:1037-1044.
  55. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, Soh D, Bilchik AJ, Katopodis N, Morton DL. Gangliosides as targets for immunotherapy of pancreatic adenocarcinoma. Cancer 2000;88:1828-1836.
  56. Habal N, Gupta R, Bilchik AJ, Johnson T, Morton DL. TA90 – IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000;7:352-356.
  57. 56. Tsioulias GT, Wood TF, Morton DL, Bilchik AJ. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg 2000;135(8):926-932.
  58. Wood TF, Rose DM, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7(8): 593-600.
  59. Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K, Gonzalez A, Tam WY, Bilchik AJ, Morton DL. Does human melanoma express carcinoembryonic antigen? Anticancer Res 2000;20(5A): 3083-3092.
  60. Wood TF, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Morton DL, Bilchik AJ. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma. Am Surg 2000;66(11):998-1003.
  61. Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 2000;75:306-310.
  62. Bilchik AJ, Tsioulias GJ, Wood TF, Morton DL. Lymphatic mapping and sentinel lymphadenectomy: a novel technique to improve staging in patients with gastrointestinal neoplasms. In ASCO 2001 Education Book, edited by Perry MC. American Society for Clinical Oncology, Alexandria, VA, 2001, pp535-540.
  63. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SS, Foshag LJ, Ramming KP. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer 2001;1(1):36-42.
  64. Bilchik AJ, Wood TF, Chung MH, Rose DM. Laparoscopic radiofrequency ablation of hepatic malignancies. In Surgical Laparoscopy, 2nd edition, edited by Zucker KA. Lippincott, Williams & Wilkins, 2001, pp 221-225.
  65. Chung MH, Foshag LJ, Bilchik AJ. Management of incidental gallbladder carcinoma following laparoscopic cholecystectomy. Contemp Surg 2001;57:506-511.
  66. Wood TF, Bilchik AJ. Radiofrequency thermal ablation as treatment for liver cancer at the John Wayne Cancer Institute. Oncology Issues 2001;16:17-20.
  67. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001;6:24-33.
  68. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Sostrin S, Turner RR, Wang H, Morton DL, Hoon DSB. Molecular staging of early colon cancer based on sentinel node analysis: A multicenter phase II trial. J Clin Oncol 2001;19:1128-1136.
  69. Miyashiro I, Kuo C, Huynh K, Iida A, Morton DL, Bilchik AJ, Giuliano A, Hoon DSB. Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes. Clin Chem 2001;47:505-512.
  70. Wood TF, Saha S, Morton DL, Tsioulias GJ, Rangel D, Hutchinson W, Foshag LJ, Bilchik AJ. Validation of lymphatic mapping in colorectal cancer: in-vivo, ex-vivo, and laparoscopic techniques. Ann Surg Oncol 2001;8:150-157.
  71. Ravindranath MH, Gonzales A, Soh D, Nishimoto K, Tam WY, Bilchik A, Morton DL, O’Day S. Interleukin-2 binds to ganglioside GD(1b). Biochem Biophys Res Commun 2001;283:369-373.
  72. Chung MH, Ye W, Ramming KP, Bilchik AJ. Repeat hepatic cryotherapy for metastatic colorectal cancer. J Gastrointest Surg 2001;5:287-293.
  73. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, DDM, Ye W, Elashoff RM. Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001;8:389-401.
  74. 73. Tsioulias GJ, Wood TF, Morton DL, Bilchik AJ. Diagnostic laparoscopy and laparoscopic ultrasonography optimize staging and resectability of intraabdominal tumors. Surg Endosc 2001;15:1016-1019.
  75. Chung MH, Wood TF, Tsioulias GJ, Rose DM, Bilchik AJ. Laparoscopic radiofrequency ablation of unresectable hepatic malignancies: a phase II trial. Surg Endosc 2001;15:1020-1026.
  76. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001;136:950-955.
  77. Wood TF, Spirt M, Rangel D, Shen P, Tsioulias GJ, Morton DL, Bilchik AJ. Lymphatic mapping improves staging during laparoscopic colectomy for cancer. Surg Endosc 2001;15:715-719.
  78. 77. Bilchik AJ, Saha S, Tsioulias GJ, Wood TF, Morton DL. Aberrant drainage and missed micrometastases: the value of lymphatic mapping and focused analysis of sentinel lymph nodes in gastrointestinal neoplasms. Ann Surg Oncol 2001;8(9S):82S-85S.
  79. Saha S, Bilchik A, Wiese D, Espinosa M, Badin J, Ganatra BK, Desai D, Kaushal S, Singh T, Arora M. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique  a multicenter trial. Ann Surg Oncol 2001;8(9S):94S-98S.
  80. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ. Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130:954-962.
  81. Yoon DY, Hines OJ, Bilchik AJ, Lewin K, Cortina G, Reber HA. Solid and papillary epithelial neoplasms of the pancreas: Aggressive resection for cure. Am Surg 2001;67:1195-1199.
  82. Taback B, Nakayama T, Wiese D, Turner R, Bilchik AJ, Saha S, Hoon D. Detection of colorectal micrometastases in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proc Am Assoc Cancer Res 2001;42:612.
  83. Perez CA, Ravindranath MH, Gupta RK, Wood TF, van de Velde CJ, Tollenar RA, Soh D, Morton DL, Bilchik AJ. Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer. Cancer J, 2002;8:55-61.
  84. Litvak DA, Wood TF, Tsioulias GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ. Systemic irinotecan and regional floxuridine following hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Onc 2002;9:148-155.
  85. Saha S, Bilchik AJ, Wiese D. Sentinel lymph-node mapping in colorectal cancer. In Colorectal Cancer: A Clinical Guide to Therapy, edited by Bleiberg H, Kemeny N, Rougier P, Wilke H.
  86. Chung MH, Gupta RK, Bilchik AJ, Ye W, Yee R, Morton DL. Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study. Current Surg 2002;59:194-8.
  87. Bilchik AJ, Nora D, Tollenaar RAEM, van de Velde CJH, Wood T, Turner R, Morton DL, Hoon DSB. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Ca 2002;38:977-85.
  88. Wood TF, Nora DT, Morton DL, Turner RR, Rangel D, Hutchinson W, Bilchik AJ. One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: Detection of missed micrometastases. J Gastrointest Surg 2002;6:322-30.
  89. Bilchik AJ, Nora DT. Lymphatic mapping of nodal micrometastasis in colon cancer: Putting the cart before the horse? Ann Surg Onc 2002;9:529-31.
  90. Tsioulias GJ, Wood TF, Spirt M, Morton DL, Bilchik AJ. A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy. Am Surg 2002;68:561-5.
  91. Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Am Surg 2002;236:438-49.
  92. Ravindranath MH, Wood TF, Soh D, Gonzales A, Muthugounder S, Perez C, Morton DL, Bilchik AJ. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 2002;45:10-21.
  93. Bilchik AJ, Nora DT, Saha S, Turner RR, Wiese D, Kuo C, Ye X, Morton DL, Hoon DS. Molecular profiling of early colon cancer predicts micrometastases. Arch Surg 2002;137:1377-1383.
  94. Bleicher RJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: Lessons learned. Ann Surg Onc 2002;10:52-58.
  95. Litvak DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy. J Gastrointest Surg 2003;7:140-148.
  96. 95. Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha SD, Krasne D, Morton DL, Bilchik AJ. Effect of lymphatic mapping on the new Tumor-Node-Metastasis classification for colorectal cancer. J Clin Onc 2003;21:668-672.
  97. Trocha S, Nora DT, Saha SS, Morton DL, Trocha SD, Wiese D, Bilchik AJ. Combination probe and dye-directed lymphatic mapping detects micrometastases in early colorectal cancer. J Gastrointest Surg 2003;7:340-346.
  98. Bilchik AJ. More (nodes) + more (analysis) = less (mortality): Challenging the therapeutic equation for early-stage colon cancer. Ann Surg Oncol 2003; 10:203-205.
  99. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang H, Hoon DSB. Quantitative c-MET mRNA expression in primary colon cancer: A predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-1488.
  100. Bilchik AJ. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: An update. Surg Onc Clin North Amer 2003;12:193-210.
  101. Yao K, Bilchik A. Local excision of a small squamous cell carcinoma of the anal canal: Case report and review of the literature. Contemp Surg, 2003;59:126-131.
  102. Curley SA, Bilchik AJ, Fraker DL, McMasters KM. Symposium: Radiofrequency ablation of hepatic malignancies. Contemp Surg, 2003;59:162-172.
  103. Litvak D, Bleicher RJ, Bilchik AJ. RFA of a refractory unresectable insulinoma of the pancreas. Contemp Surg 2003;59:229-232.
  104. Turner RR, Nora DT, Trocha SD, Bilchik AJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and non-sentinel lymph nodes. Arch Path Lab Med 2003;127:673-679.
  105. Bleicher RJ, Bilchik AJ. Complications of hepatic RFA: Lessons learned. In Radiofrequency Ablation of Cancer: Current Indications, Techniques, and Outcomes, edited by Ellis LM, Curley SA, Tanabe KK. Springer-Verlag, New York, 2003, pp 121-134.
  106. Bilchik AJ. Thermal ablation of hepatic colorectal metastasis: should this minimally invasive technique replace resection? In ASCO 2003 Education Book, edited by Perry MC. American Society for Clinical Oncology, Alexandria, VA, 2003, pp 699-710.
  107. Morton DL., Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, Elashoff R. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-550.
  108. Bilchik AJ, Trocha SD. Lymphatic mapping and sentinel node analysis to optimize laparoscopic resection and staging of colorectal cancer: An update. Cancer Control 2003;10:219-223.
  109. Trocha SD, Saha SS, Wiese D, Thompson J, Morton DL, Bilchik AJ. Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: Impact on adjuvant treatment. Am Surg 2003;69:918-922.
  110. Bilchik AJ, Faries M. Radiofrequency ablation of hepatic malignancies: Inexpensive and minimally invasive, but should it replace resection? Ann Surg Oncol 2003;10:1002-1004.
  111. Bilchik AJ, Essner R, Thompson JF, Morton DL. Hepatic surgery for metastatic melanoma. In Textbook of Melanoma: Pathology, Diagnosis and Management, edited by Thompson JF, Morton DL, Kroon BBR. Martin Dunitz Publishers, London, 2004, pp 505-513.
  112. Taback B, Bilchik AJ, Saha S, Nakayama T, Wiese DA, Turner RR, Kuo CT, Hoon DSB. Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 2004; 111: 409-414.
  113. Bilchik AJ, Martinez S. Novel effective drugs and evolving ablation technology: A more comprehensive approach to hepatic malignancies. Ann Surg Oncol 2004; 11: 458-459.
  114. Saha S, Dan AG, Bilchik AJ, Kitagawa Y, Schochet E, Choudri S, Saha L, Wiese D, Morton D, Kitajima M. Historical review of lymphatic mapping in gastrointestinal malignancies. Ann Surg Oncol 2004; 11: 245S-249S.
  115. Umetani N, Fujimoto A, Takeuchi H, Shinozaki M, Bilchik AJ, Hoon DS. Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colon carcinoma. Oncogene 2004; 23(50): 8292-300.
  116. cancer (T1 & T2) by sentinel lymph node (SLN) mapping. Ann Surg Oncol 2004;11(2):S109-S110.
  117. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res 2004; 10:7475-7483.
  118. Martinez SR, Bilchik AJ. Quality control issues in the management of colon cancer patients. Eur J Surg Onc, 2005; 31: 616-629.
  119. Martinez S, Bilchik AJ. Lymphatic mapping and sentinel node analysis in colon cancer: A review. Clinical Colorectal Cancer, 2005; 4: 320-324.
  120. Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, Foshag L, Bilchik AJ, Hoon DSB. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23:2744-2753.
  121. Takeuchi H, Kim J, Fujimoto A, Umetani N, Mori T, Bilchik AJ, Turner R, Tran A, Kuo C, Hoon DS. X-linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-Met pathway via AKt signaling. Clin Cancer Res 2005; 11:7621-7628.
  122. 121. Bilchik AJ, Poston G, Curley SA. Strasberg S, Saltz L, Adam R, Nordlinger B, Rosen LS, Rougier P. Neoadjuvant
  123. Martinez SR, Young SE, Giuliano AE, Bilchik AJ. The utility of estrogen receptor, progesterone receptor and HER-2/neu status to predict survival in patients undergoing resection for breast cancer metastases. Am J Surg 2006; 191:281-283.
  124. Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, Beutler T, Wiese D, Bassily N, Yee C. A multicenter trial of sentinel lymph node mapping in colorectal cancer:prognostic implications for nodal staging and recurrence. Am J Surg 2006; 19:305-310
  125. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113-120
  126. Chen, SL, Iddings DM, Schrei RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin 2006;56:292-309
  127. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving respectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-80
  128. 127. Zogakis TG, Bilchik AJ. Radiofrequency thermal ablation of liver tumors. In Textbook Surgery of the Liver, Biliary Tract and Pancreas, 4th Edition, edited by Blumgart LS, Belghiti J. Elsevier, Philadelphia, PA, October 2006
  129. Kim J, Takuji M, Amersi F, Martinez S, Kuo C, Turner RR, Yi C, Bilchik AJ, Morton DL, Hoon DSB. Chemokine receptor CXCR4 expression by melanoma and colorectal cancer facilitates liver metastasis and correlates with disease outcome. Ann Surg Oncol, 2006; 244(1) 113-120.
  130. Martinez SR, Young SE, Hoedema R, Foshag LJ, Bilchik AJ. Colorectal cancer screening and surveillance: Current standards and future trends. Ann Surg Oncol 2006; 13(6):768-775.
  131. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, Amersi FF, Martinez SR, Dry SM, Bilchik AJ, Hoon DSB. The clinical significance of MAGE-3 expression in pancreatic cancer. Int J Cancer, 2006; 118(9) 2269-2275.
  132. Bilchik AJ. Novel Insights into the Diagnosis and Treatment of Melanoma. In Melanoma- Surgical Oncology Clinics of North America, edited by Petrelli N, Bilchik AJ, Elsevier, Philadelphia, PA, 2006; 240pgs
  133. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long Term Survival after Radiofrequency Ablation of Complex Unresectable Liver Tumors. Arch Surg, 2006;141(6):581-588
  134. Bilchik AJ, DiNome M, Saha S, Turner R, Wiese D, McCarter M, Hoon DSB, Morton DL. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg, 2006;141(6):527-534
  135. Martinez S, Chen S, Bilchik AJ. Treatment disparities in Hispanic rectal cancer patients: a SEER database study. Am J Surg 2006;72:906-908
  136. Aikou T, Kitagawa Y, Kitajima M, Uenosono Y, Martinez SR, Bilchik AJ, Saha S. Sentinel Lymph Node Mapping for GI Cancer. Cancer Metastasis Reviews (supplemental issue), 2006; 25(2):269-277.
  137. Umetani N, Kim J, Hiramatsu S, Bilchik AJ, Reber HA, Hines OJ, Hoon DS. Elevated integrity of free circulating DNA in sera of colorectal and periampullary cancer patients: A direct quantitative PCR for ALU repeats. Clin Chem, 2006;52(6) 1062-1069.
  138. Kim J, Reber HA, Dry SM, Elashoff D, Chen S, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, Hoon D. Unfavorable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut, May 2006;55:1598-1605.
  139. Iddings DM, Ahmad A, Elashoff D, Bilchik AJ. The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-analysis. Ann Surg Oncol, 2006;13:1386-1392
  140. Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244:602-610
  141. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg. 2006;72(10):875-9
  142. Bilchik AJ. Colorectal cancer metastatic to the liver: radiofrequency ablation. In Current Surgical Therapy, edited by Cameron JL. Ninth edition. Elsevier, Philadelphia, 2007
  143. Bilchik AJ. Current and emerging trends in the treatment of early-stage colorectal cancer: importance of a multidisciplinary approach. Hematol Oncol Clin, North Am 2007;21(Suppl 1):8-18
  144. Bilchk, AJ. Summary on “More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study”. NEJM, 2007
  145. Kavanagh MA, Ahmad A, Amadpour M, Bilchik AJ. Image of the month: serrated adenomatous polyposis. Arch Surg 2007; 142(9):902
  146. Nicholl MB, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver metastases Current Colorectal Cancer Reports. Volume 3: Issue 2, April 2007;3: 99-103
  147. Iddings DM, Koda EA, Gewel SS, Parker R, Saha D, Bilchik AJ. Angiogenesis markers in early colorectal cancer predict lymph node metastases. Arch Surg, 2007; 142:738-745
  148. Chen SL, Bilchik AJ. Resecting lymph nodes in colon cancer: more than a staging operation? Ann Surg Oncol 2007; 14:2175-2176
  149. Iddings DM, Bilchik AJ. Gastric Carcinoma: Applying the sentinel node paradigm to improve the Understanding of metastatic patterns and the possible role of selective lymphadenectomy. Ann Surg Oncol 2007; 14:2432-2434
  150. Bilchik, AJ, Compton C. Close collaboration between surgeon and pathologist is essential for accurate Staging of early colon cancer. Ann Surg, 2007;245:864
  151. Ahmad A, Chen SL, Bilchik, AJ. Role of repeated hepatectomy in the multimodal treatment of Hepatic colorectal metastases. Arch Surg 142:526-531, 2007
  152. Wright BE, Lee C, Bilchik AJ. Hepatic cytoreductive surgery for neuroendocrine cancer. Surg Oncol Clin N Am, 2007;16:627-637
  153. 152. Iddings D, Bilchik AJ. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. Seminars in Surgical Oncology. J Surg Oncol, 2007:96(8);671-678
  154. Wright BE, Bilchik AJ. Management of T2 Gallbaladder Cancer: Are practice patterns consistent with national recommendations? Am J Surg Dec 2007; 194(6):820-826
  155. Bilchik AJ, Hoon DSB, Saha S, Weise D, DiNome M, Turner R, Koyanga K, McCarter M, Shen P, Iddings D, Chen SL, Gonzales M, Elashoff D, Morton DL. Prognostic Impact of Micrometastases In Colon Cancer: Interim Results of A Prospective Multicenter Trial. Annals of Surg 2007;246(4):568-577
  156. Rosen L, Bilchik AJ, Beart RW, Benson AB, Chang KJ, Compton CC, Grothey A, Haller DH, Ko CY, Lynch PM, Nelson H, Stamos M, Turner R, Willett CG. New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer. Clin Cancer Research 2007;13:6853-6
  157. de Maat MF, Van de Velde C, Umetani N, de Heer P, Putter H, Van Hoesel A, Meijer GA, Van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar R, Hoon DS. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. J Clin Oncol 2007; 25:4887-4894
  158. Bilchik AJ. Current and Emerging Strategies for the Treatment of Unresectable Hepatic Neuroendocrine Metastases. A century of Advance in Neuroendocrine Tumor Disease, 2008; 427-433
  159. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer (commentary)? Ann Surg Oncol, 2008:15(1);1-3
  160. Iddings DM, Wright BE, Bilchik AJ. A rare cause of primary hepatic neoplasm: malignant peripheral nerve sheath tumor (MPNST) in the age of modern liver surgery. Am Surg, 2008; 74:47-50
  161. Nicholl, M, Bilchik AJ. Thermal Ablation of Hepatic Malignancy: Useful But Still Not Optimal. Eur J Surg Oncol, 2008; 34:318-23
  162. Koyanagi K, Bilchik AJ, Saha S, Turner RR, et al. Clinical relevance of occult nodal micrometastases and circulating tumor cells in early colorectal cancer in a prospective multicenter trial. Clin Cancer Research 2008; 22:7391-7396
  163. deMaat M, van de Velde C, van der Werff M, Putter H, Umetani N, Klein-Kranenbarg E, Turner R, van Krieken J, Bilchik AJ, Tollenaar R, Hoon D. Quantitative Analysis of Methylation of Genomic Loci in Early Stage Rectal Cancer Predicts distant Recurrence. J Clin Oncol 2008; 26:2327-35
  164. Bilchik AJ, Hecht JR. Perioperative Risks of Bevacizumab and other Biological Agents for Hepatectomy: Theoretical or Evidence Based? J Clin Oncol 2008; 26:1786-9
  165. Wasif N, Sasu S, Conway W, Bilchik AJ. Focal Nodular Hyperplasia (FNH): Report of an Unusual Case and Review of the Literature. Am Surg 2008; 74:1100-1103
  166. Graeme J Poston, Joan Figueras, Felice Giuliante ,Gennaro Nuzzo, Alberto F Sobrero, Jean-Francois Gigot, Bernard Nordlinger, Rene Adam, Thomas Gruenberger, Michael A Choti, Anton J Bilchik, Eric Van Cutsem, Michael I D’Angelica. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 29:4828-4833
  167. Telian SH, Bilchik AJ. Significance of the Lymph Node Ratio in Stage III Colon Cancer. Ann Surg Oncol 2008; 6:1557-1558
  168. Stojadinovich A, Nissan A, Protic M, Bilchik AJ, Peoples G. Targeted Nodal Assessment in Colon Cancer. Ann Surg 2008; 5:902-904
  169. Bilchik AJ, Poston G, Adam R, Choti M. Prognostic Variables for Colorectal Cancer Hepatic Metastases: An Evolving Paradigm! J Clin Oncol 2008; 26:5320-5321
  170. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer? Ann Surg Oncol 2008; 1:1-3
  171. Bilchik AJ, Stojadinovic A, Wainberg Z, Hecht JR. Targeted lymph node evaluation in colorectal cancer: a decade of progress! J Surg Oncol 2009 5:273-274
  172. Cahill RA, Bembenek A, Sirop S, Waterhouse DF, Schneider W, Leroy J, Wiese D, Beutler T, Bilchik AJ, Saha, S, Schlag PM. Sentinel node biopsy for individualization of surgical strategy for cure of early-stage colon cancer, Ann Surg Oncol 2009:16;2170-80.
  173. Nissan, A, Protic P, Bilchik AJ, Eberhardt J, Peoples GE, Stojadinovic, A. Predictive Model of Outcome of Targeted Nodal Assessment in Colorectal Cancer. Annals of Surgery 2010:251;265-74.
  174. Bilchik AJ. Ablation of Hepatic Malignancies: From Radiofrequency to Microwave – A New Generation of Technology. Journal of Interventional Oncology 2009:2;121-127.
  175. Wasif N, Faries MB, Saha S, Turner RR, Wiese D, McCarter M, Shen P, Stojadinovic A, Bilchik AJ. Primary colorectal tumor characteristics as predictors of occult nodal metastasis in a prospective multicenter trial Surgery, 2010:147;352-7.
  176. Bilchik AJ, Nissan A, Wainberg Z, Shen P. Surgical Quality and Nodal Ultra-staging is Associated with Long-term Disease-free Survival in Early Colorectal Cancer: An Analysis of Two International Multi-center Prospective Trials. Annals of Surgery, 2010:252;467-74
  177. Bilchik AJ, Gonzalez M, Stojadinovic, A. The Applications of Sentinel Lymph Node to Cancer. In Press Advances in Minimally Invasive Surgery. Ed Fred Greene
  178. Nicholl MB, Conway W, Ye X, Bilchik AJ, Singh G. Should Microwave Energy Be Preferred to Radiofrequency Energy for Malignant Liver Tumor Ablation? J Interventional Oncology 2010:3(1); 201-210.
  179. Bilchik, AJ, Stojadinovic A. Is it time to move beyond lymph node evaluation in staging colon cancer? Arch Surg. 2010 Sep;145(9):830-1.
  180. Steele SR, Chen SL, Stojadinovic A, Nissan A, Zhu K, Peoples GE, Bilchik AJ. The impact of age on quality measure adherence in colon cancer. J Am Coll Surg. 2011 May 19. [Epub ahead of print]
  181. Soni M, Wiese D, Korant A, Sirop S, Chakravarty B, Gayar A, Bilchik AJ, Beutler T, Ratz D, Saha S. .Comparison of nodal positivity between SLNM vs conventional surgery in colon cancer patients with <12 and ≥12 lymph nodes harvested. Am J Surg. 2011 Jan 29. [Epub ahead of print]
  182. Chen SL, Steele SR, Eberhardt J, Zhu K, Bilchik AJ, Stojadinovic A. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg. 2011 Jan;253(1):82-7.
  183. Garreau, J, Wasif, N., Yao, K., Bilchik, AJ. Treatment Patterns for Micrometastases of Colon Cancer. Submitted American J Surgery 2011
Published Abstracts:    
   
  1. Adrian T, Zucker KA, Bilchik AJ, Modlin IM. Cholecystokin receptor antagonist blocks diet-induced pancreatic hypertrophy in the hamster. Clin Res 1987;35(5):796A.
  2. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Amelioration of traumatic pancreatitis by a new specific CCK receptor antagonist. Gastroenterology 1988;94:A35.
  3. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM. Cholecystokinin receptor antagonist blocks fat induced pancreatic growth but increases food intake and body weight in the hamster. Gastroenterology 1988;94:A3.
  4. Longo WE, Ballantyne GH, Vukasin AP, Bilchik AJ, Adrian TE, Modlin IM. Bile salts release peptide tyrosine tyrosine. Gastroenterology 1988;94:A269.
  5. Bilchik AJ, Fielding LP, Basson MD, Zucker KA, Ballantyne GH, Adrian TE, Modlin IM. Postpransial portosystemic differences in secretion and somatostatin release in the dog. Gastroenterology 1988;94:A34.
  6. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM. Is cholecystokinin responsible for normal pancreatic growth? Gastoenterology 1988;94:A518.
  7. Adrian TE, Bilchik AJ, Zucker KA, Modlin IM. CCK receptor blockade increases hamster body weight and food intake. FASEB Journal 1988;2(4):A737.
  8. Bilchik AJ, Zucker KA, Sussman J, Adrian TE, Modlin IM. New specific CCK receptor antagonist ameliorates surgically induced pancreatitis both pre and post insult. Br J Surg 1988.
  9. Bilchik AJ, Nilsson O, Modlin IM, Zucker KA and Adian TE. Rapid carcinoid tumor induction in mastomys with H2 receptor blockade. Connecticut Med 1988.
  10. Armstrong DN, Bilchik AJ, Adrian TE, Zucker KA, Modlin IM. PYY and enteroglucagon levels are elevated after proctocolectomy and pelvic ileal-anal anastomosis. Gastroenterology 1989;96:A15.
  11. Bilchik AJ, Zucker KA, Adrian TE, Modlin IM. Parenteral, but not oral L369,718 ameliorates acute experimental pancreatitis. Gastroenterology 1989;96;A45.
  12. Zucker KA, Bilchik AJ, Leach SD, Adrian TE, Modlin IM. Continuous cholecystokinin receptor blockade in newborn guinea pigs: impaired growth and altered secretagogue response. Gastroenterology 1989;96;A568.
  13. Nillson O, Bilchik AJ, Adrian TE, Modlin IM. Gastric carcinoids of praomys natalensis contain PYY and enteroglucagon like immunoreactivity. Gastroenterology 1989;96;A366.
  14. Savoca PE, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM. Xylocaine does not inhibit deoxycholate stimulated PYY release. Gastroenterology 1989;96;A444.
  15. Vukasin AP, Ballantyne GH, Adrian TE, Bilchik AJ, Pernikoff B, Modlin IM. Elevations in plasma and tissue PYY after colectomy. Gastroenterology 1989;96.
  16. Modlin IM, Bilchik AJ, Kacinski B, Esterline W, Goldenring JR. Oncogene amplification in gastric carcinoid tumors induced by acid secretory blockade in mastomys. Gastroenterology 1990.
  17. Bilchik AJ, Hines OJ, Zinner MJ, Adrian TE, McFadden DW, Ashley SW. Physiological significance of PPY in small intestinal absorption in vivo. Gastroenterology 1993;623:A157.
  18. Bilchik AJ, Hines OJ, Zinner MJ, Berger JJ, McFadden DW, Adiran TE, Ashley SW. PYY augments postprandial small intestinal absorption in vivo. Gastroenterology 1993;506:A127.
  19. Hines OJ, Bilchik AJ, Rodgers PJ, Berger J, Zinner MJ, Ashley SW. Na+/H+ exchange regulates postprandial ileal absorption. Gastroenterology 1993;611:A153.
  20. Kelley MC, Bostick P, Bilchik AJ, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular detection of pancreatic carcinoma (PC) with a multiple marker RT-PCR assay. Proc Am Soc Clin Oncol 1997;16:293a.
  21. Sarantou T, Bilchik AJ, Ramming K. Cryoablation of primary and metastatic liver cancer unresponsive to conventional therapy. Proc Am Soc Clin Oncol 1997;16:304a.
  22. Bilchik AJ, Ravindranath MH, Chu KU, Soh D, Morton DL. Polyvalent vaccine includes an immune response to carbohydrate antigens in stage IV colon cancer. Proc Am Soc Clin Onc 1999;18:455a.
  23. Bilchik AJ, Chawla S, Rose DM, Stern S, Ramming KP. Systemic irinotecan (CPT-11) and regional chemotherapy prolong survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil (5-FU). . Proc Am Soc Clin Onc 1999;18:254a.
  24. Chu KU, Ravindranath MH, Nishimoto K, Bilchik AJ, Morton DL. Cell-surface expression of an immunogenic ganglioside (GM2) in pancreatic adenocarcinoma. Proc Am Assoc Cancer Res 1999;40:470a.
  25. Ravindranath MH, Bilchik AJ, Chu K, Soh D, Shen P, Morton DL. Anti-GM2 IgM inversely correlates with the serum ganglioside level in colon cancer patients after vaccine therapy. Proc Am Assoc Cancer Res 1999;40:577a.
  26. Bilchik AJ, Saha S, Stonecypher JA, Wood TF, Hoon DS. Molecular staging of early colon cancer: lymphatic mapping and sentinel node analysis for occult micrometastasis. Proc Am Soc Clin Oncol 2000;19:248a.
  27. Saha S, Bilchik AJ, Wiese D, Nora D, Badin J, Espinosa M, Ganatra BK, Seoane S, Gomez E, Singh T, Arora M. Phase II study for upstaging of colorectal cancer (CRCA) by sentinel lymph node mapping (SLNM) technique - a multicenter trial. Proc Am Soc Clin Oncol 2000;19:239a.
  28. Bilchik AJ, Ravindranath M, Gupta R, Habal N, Wood TF, Tsioulias GJ, Morton DL. CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon cancer: a phase II trial. Proc Am Soc Clin Oncol 2001;20:252a.
  29. Ravindranath MH, Wood TF, Soh D, Perez C, Gonzales AM, Morton DL, Bilchik AJ. Necrosis induced by cryotherapy of liver metastases increases serum ganglioside levels and provides an intrinsic adjuvant to augment specific IgM to tumor-associated gangliosides. Proc Am Assoc Cancer Res 2001;42:507a.
  30. Saha S, Bilchik A, Espinosa M, Monson K, Nadimpalli R, Wiese D, Ganatra K, Desai D, Kaushal S, Nagaraju M. Results of a multi-institutional trial of sentinel lymph node mapping (SLNM) in colorectal cancer (CRCa). Proc Am Soc Clin Oncol 2001;584.
  31. Taback B, Nakayama T, Wiese D, Turner R, Bilchik A, Saha S, Hoon D. Detection of colorectal micrometastasis in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proc Am Assoc Cancer Res 2001;42:612a.
  32. 32. Bilchik AJ, Perez CA, Tollenar W, Morton DL, van de Velde CJ. Multivariate analysis of 18 prognostic factors in early colon cancer: a prospective, multi-center trial. Proc Am Soc Clin Oncol 2002;21:172a.
  33. Nora DT, Kadison AS, Trocha S, Riley C, Bilchik AJ, Morton DL. Does nodal micrometastasis alter the staging and management of early stage colorectal cancer? Proc Am Soc Clin Oncol 2002;21:117b.
  34. Takeunchi H, Bilchik A, Saha S, Wiese D, Kuo C, Ye X, Hoon DSB. C-Met gene expression in primary colorectal cancer correlates with depth of tumor invasion and metastatic potential. Proc Am Assoc Cancer Res 2002;43:217.
  35. Litvak, DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism enhance irinotecan-mediated apoptosis of colon cancer cells by a p53-independent process. Ann Surg Oncol 2002;9(1):S10-S11
  36. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 406 complex unresectable liver tumors: Lessons learned. Ann Surg Oncol 2002;9(1):S8.
  37. Yao K, Nora D, Ye X, Morton D, Bilchik A. Micrometastases in colon cancer: Perception versus reality. Ann Surg Oncol 2003;10(1):S62.
  38. Kim J, Takeuchi H, Foshag L, Bilchik A, Hoon DSB. Colorectal cancer expression of chemokine receptor CXCR4 promotes liver metastasis. Proc Am Soc Clin Oncol 2004; 23:266.
  39. Kim J, Mori T, Lam S, Nguyen L, Morton D, Bilchik AJ, Hoon DSB. CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver. J Am Coll Surg 2004; 199(3S):81.
  40. Umetani N, Shinozaki M, Fujimoto A, Takeuchi H, Bilchik AJ, Hoon DS. Allelic loss at the APAF-1 locus facilitates colorectal carcinogenesis and metastasis to the liver. Proc Am Assoc Cancer Res 2004;45:764-765.
  41. Saha S, Dan AG, Bilchik AJ, Beutler T, Doan K, AlSamkari R, Wiese D, Turner R, Barber K. Mechanisms of failure and skip metastasis in sentinel lymph node mapping for colorectal cancer. Ann Surg Oncol 2005;12(2):S83.
  42. Martinez SR, Kuo CT, Bilchik AJ, Kim J, Morton DL, Hoon DSB. Downregulation of tumor suppressor Runx genes in malignant cutaneous melanoma. J Clin Oncol 2005; 23:717S.
Invited Participant, Lectureships and Presentations:    
1st International Workshop on Neuroimmunomodulation    
1990  

Presented The Neuroimmunomodulatory role of cholecystokinin.

1st Multidisciplinary Colorectal Cancer Congress  

 

2001  

Presented Local Treatment of liver metastases

           
10th World Congress of Cryosurgery  

 

1998  

Presente A 5-year institutional experience with hepatic cryosurgery for unresectable colorectal metastases refractory to chemotherapy.

1998  

Presented  An alternative strategy in the treatment of patients with unresectable hepatomas.

23rd annual Gary Wratten Surgical Symposium    
2001  

Senior Author - Presentation Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: a pilot study.

38th World Congress of Surgery    
1999  

Presented Prognostic factors and the role of chemotherapy in 153 patients undergoing cryosurgery for unresectable colorectal metastasis. 

American Association of Endocrine Surgeons    
1989  

Presented H2 receptor blockade induction peptide YY (PYY) and enteroglucagon (EG) secreting gastric carcinoids in mastomys. 

1994  

Presented Peptide YY immunoneutralizaton inhibits meal induced absorption in vivo.

1997  

Presented Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy.

2001  

Senior Author - Presentation Hepatic cytoreduction followed by a novel long-acting somatostatin analogue: a paradigm for intractable neuroendocrine tumors metastatic to the liver.

American Cancer Society’s 41st Science Writers Seminar    
1999  

Presented Universal application of the sentinel node technique in solid cancers.

American College of Surgeons, Clinical Congress    
1998  

Presented Detection of pancreatic carcinoma with a novel multi-marker RT-PCR assay.

1998  

Presented Gangliosides as potential immunotherapy targets in pancreatic cancer.

2000      

Invited Lecturer Evolving techniques for treatment of metastatic tumors.

2001   Invited Lecturer Vaccine Immunotherapy with CancerVax in Advanced Colon Cancer.
2001   Invited Lecturer Lymphatic mapping and sentinel node analysis improves staging accuracy in gastrointestinal neoplasms.
2001  

Invited Discussant Treatment of Pancreatic Pseudocyst of Percutaneous Endoscopic Cystogastrostomy.

2002   Invited Lecturer Sentinel lymph node resection for colorectal cancer.

2003   2003 Presented Missed micrometastases and aberrant drainage patterns: Challenging the therapeutic equation in gastrointestinal neoplasms
2003   Invited Lecturer Ablative techniques: RFA vs. cryosurgery
2003   Invited Lecturer Sentinel node discussion for G.I. malignancies
2004   2004 Invited Lecturer Ablative techniques for metastatic malignancies: minimally invasive but should they replace resection?
2004   Invited Lecturer Lymphatic Mapping in Gastrointestinal Neoplasms: Challenging the Therapeutic Equation
2004   Contributing Author CXCR4 chemokine receptor mediates melanoma and colorectal cancer metastasis to the liver.
2004   Invited Lecturer Complications of Radiofrequency Ablation: When to use it and when not to?
2005   2005 Invited Lecturer Lymphatic Mapping in Gastrointestinal Neoplasms: Challenging the Therapeutic Equation
2006   2006 Invited Lecturer Integration of New Ablation Technologies with Hepatic Resection and Systemic Therapy
2007   2007 Invited Lecturer Lymphatic Mapping in Gastrointestinal Neoplasms
2009   Invited Lecturer Ablation for Early Hepatocellular Carcinoma.
American College of Surgeons Oncology Group    
1999-2001   Invited Participant / Co-Investigator Lymph node mapping and sentinel lymph node biopsy for stage I, II, III colon cancer.
American College of Surgeons, Northern California Chapter    
2003   Invited Lecturer Radioguided surgery: Technologic advance or marketing gimmick!
American College of Surgeons, Southern California Chapter    
1999   Senior Author – Presentation Radiofrequency ablation – A novel primary and adjunctive technique for hepatic malignancies.
2000   Senior Author – Presentation Focused examination of sentinel lymph nodes upstages early colorectal carcinoma.
2001   Senior Author - Presentation A novel lymphatic mapping technique to improve cancer staging during laparoscopic colectomy.
2003   Contributing Author – Poster Presentation Chronic management of recurrent hepatic tumors using sequential radiofrequency ablation.
2003   Senior Author – Presentation Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: Impact on adjuvant treatment.
2006   Senior Author – Poster Presentation Radiofrequency ablation for hepatic metastases: do the newer probes decrease recurrence?
2006   Senior Author – Presentation Treatment disparities in Hispanic rectal cancer patients: a SEER database study.
2007   Invited Lecturer Treatment of Colorectal Liver Metastases. What are the limits? What are the goals?
2008   2008 Senior Author – Presentation Treatment patterns for micrometastases of colon cancer.
2011   Senior Author - Presentation Adjuvant treatment of early colon cancer with micrometastases: results of a prospective multicenter phase 2 trial and national survey.
American College of Surgeons Surgical Forum    
2001   Contributing Author - Presentation Targeting ceramide metabolism – A novel strategy for colon cancer therapy.
American Gastroenterological Association    
1988   Presented Amelioration of traumatic pancreatitis by CCK receptor antagonists.
1988   Presented Is cholecystokinin an essential pancreatic growth factor?
1993   Presented Physiological significance of PYY in small intestinal absorption in vivo.
1993   Presented Na+/H+ exchange regulates postprandial ileal absorption.
2000   Presented Molecular staging of colon cancer using a novel approach: A multi-center phase II trial.
2004   Invited Lecturer Laparoscopic Lymphatic Mapping: “Challenging the Therapeutic Equation in Colon Cancer”
2005   Contributing Author – Poster Presentation MAGE-A3 expression correlates with disease outcome in pancreatic cancer.
2006   Contributing Author – Poster Presentation Epigenetic inactivation of WNT inhibitory factor-1 gene promotes colorectal tumorigenesis.
American Hepato Pancreato Biliary Association    
2005   Invited Lecturer Laparoscopic Radiofrequency Ablation
2008   2008 Invited Lecturer Radiofrequency Ablation of Liver Tumors: What are the Limits? What are the Goals?
2009   2009 Invited Lecturer A Multidisciplinary Approach to Hepatic Colorectal Metastases
2011   Discussant Resection vs Radiofrequency Ablation for Colorectal Liver Metastases
American Radium Society    
1998   Poster presentation An alternative strategy in the treatment of patients with unresectable hepatomas.
1998   Presented Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms.
1998   Presented Cryosurgery of hepatocellular carcinoma.
1999   Presented Radiofrequency ablation – a novel, minimally invasive technique with multiple applications.
2001   Senior Author –Presentation TA90-IC and Anti-GM2 IgM response: novel immunologic markers in colorectal cancer and predictors of survival.
American Society of Clinical Oncology    
1997   Presented Cryoablation of primary and metastatic liver cancer unresponsive to conventional therapy.
1999   Poster Presentation Systemic irinotecan (CPT-11) and regional chemotherapy prolong survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5- fluorouracil (5-FU).
1999   Published Abstract Polyvalent vaccine induces an immune response to carbohydrate antigens in stage IV colon cancer.
2000   Poster Presentation Molecular staging of early colon cancer: Lymphatic mapping and sentinel node analysis for occult micrometastases.
2001   Invited Lecturer Sentinel node technique for staging and treatment decisions.
2001   Presented CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon cancer: A phase II trial.
2002   Poster Presentation Multivariate analysis of 18 prognostic factors in early colorectal cancer: a prospective multicenter trial.
2003   Invited Lecturer Thermal ablation of hepatic colorectal metastasis: Should this minimally invasive technique replace resection?
2003   Invited Lecturer The impact of lymphatic mapping and sentinel lymph node analysis on gastrointestinal neoplasms.
2005   Invited Lecturer Therapeutic options for unresectable hepatic metastases: What are the limits? What are the goals?
2006   Invited Lecturer Integration of New Ablation Technologies with Hepatic Resection and Systemic Therapy
American Society of Clinical Oncology-Gastrointestinal Cancers Symposium    
2006   Senior Author- Presentation (Poster) A comparison of oxaliplatin-based adjuvant chemotherapy versus improved nodal sampling for stage II colon cancer: cost-effectiveness and survival
American Surgical Association    
2002   Co-Author – Oral Presentation Long-term results of lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Implications of nodal microanatomy and molecular staging on detection of nodal micrometastases.
2006   Senior Author-Oral Presentation Does more extensive nodal dissection improve survival for resectable colon cancer? A population based study.
2007   Presented Prognostic Impact of Micrometastases in Colon Cancer: Interim Results of a Prospective Multicenter Trial.
2010   Presented Surgical Quality and Nodal Ultra-staging is Associated with Long-term Disease-free Survival in Early Colorectal Cancer: An Analysis of Two International Multi-center Prospective Trials.
Association of Academic Surgeons    
1989   Presented Continuous cholecystokinin receptor blockade in newborn guinea pigs impaired growth and altered secretagogue response.
1989   Presented Manipulation of subcellular pH during experimental acute pancreatitis.
1993   Presented A unique hormonal mediator of intestinal glucose transport and paracellular permeability.
1993   Presented Adaptation of Na+/glucose co-transporter following intestinal resection.
1993   Presented Mechanisms of EG synthesis and release after massive small bowel resection.
Association of Veterans Administration Surgeons    
1989   Presented Peptide YY release from short chain fatty acids: Evidence of human colonic evolution?
1990   Presented Amelioration of cholinergic induced pancreatitis with a selective cholecystokinin receptor antagonist.
Boerhaave Professorship    
2001   Visiting Professor, University of Leiden, Netherlands Colorectal Cancer.
Brooklyn Surgical Society    
2008   Visiting Professor, Lymph nodes: More than a staging operation in early colon cancer?
Carcinoid Fighters    
2002-2006   Invited Lecturer Aggressive cytoreduction improves symptoms in patients with refractory neuroendocrine tumors.
Cedars Sinai Grand Rounds    
2004   Invited Lecturer Missed Micrometastases and Aberrant Drainage Patterns: Challenging the Therapeutic Equation in Gastrointestinal Neoplasms.
2009   Invited Lecturer Advances in the Management of Colorectal Hepatic Metastases: A Multidisciplinary Approach.
Cell Biology    
1989   Presented PYY, SRIF, PP and EG colocalization in the rodent pancreas.
A Century of Advances in Neuroendocrine Tumors-A Tribute to Siegfried Oberndofer    
2007   Invited Lecturer Current and Emerging Strategies for the Treatment of Unresectable Hepatic Neuroendocrine Metastases
Circulating Nuclei Acids in Plasma and Serum    
2005   Contributing Author – Poster presentation Detection of gastrointestinal cancers by free circulating DNA integrity in serum using quantitative PCR.
Colon and Rectal Cancers-New Approaches to Assessing and Treating Early Stage Colon and Rectal Cancers    
2007   Invited Lecturer Surgeon or the Pathologist as a prognostic factor in Colorectal Cancer
Connecticut Chapter of the American College of Surgeons    
1988   Presented 1st prize awarded cancer competition 1988 Rapid carcinoid tumor induction in mastomys with H2 receptor blockage.
Creighton University Department of Biomedical Sciences    
1989   Visiting Lecturer Investigation into biochemistry and pathophysiology of a novel gastric endocrine tumor model.
CURE/UCLA    
1993   Presented Role of Na+/glucose co-transporter in meal-induced proabsorption.
Current Trends in Colorectal Cancer Series    
2005   Invited Lecturer Thermal Ablation of Hepatic Colorectal Metastases.
Downstate University    
2008   Grand Rounds: Hepatectomy for colorectal liver metastases: What are the limits, what are the goals?
Federation of American Experimental Societies for Biology    
1988   Presented CCK receptor blockade increases hamster body weight and food intake.
Harbor-UCLA Medical Center    
2003   Invited Lecturer – Surgery Grand Rounds Radiofrequency ablation of hepatic colorectal metastases: Minimally invasive, but should it replace resection?
Hoag Hospital    
2007   Invited Lecture-Grand Rounds Treatment of Colorectal Liver Metastases What are the limits? What are the goals?
International Conference on Gastroenteric Biology    
1988   Presented A novel micro-method for pancreatic acinar secretion: Time course of CCK stimulation and its inhibition by L364, 718.
International Sentinel Node Congress    
2000   Presented Lymphatic mapping and focused analysis of the sentinel lymph node upstages gastrointestinal neoplasms.
2002   Invited Lecturer The impact of lymphatic mapping and sentinel node analysis on the new staging system for colon cancer.
2004   Contributing Author – Oral presentation A comparison of various tracers for lymphatic mapping for colorectal cancer.
2004   Invited Lecturer Current Status and Future Colon Sentinel Node Surgery
2004   Invited Lecturer Meet the professors- GI Cancers Breakfast
2004   Contributing Author – Poster presentation Comparative analysis of nodal metastasis for T3 and T4 colon cancer between sentinel lymph node mapping vs. conventional surgery.
McLaren Regional Medical Center    
1999   Visiting Lecturer 8th Annual “Advances in Cancer Therapy.”
MD Anderson Cancer Center    
2008   Visiting Lecturer Resecting Lymph Nodes In Colon Cancer: More than a staging operation?
Medtronic Colorectal Cancer Symposium    
2002   Presented Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases.
National Cancer Institute, Organ Systems Branch    
1999   Participant “Pancreatic Cancer Think Tank.”
National Gut Hormone Symposium    
1988   Presented CCK and a new surgical model of pancreatitis.
New England Society of Colon and Rectal Surgeons    
1989   Presented. Release of peptide YY in humans.
Oncology:Clinical Issues and Trends    
2006   2006 Invited Lecturer Advances in the Surgical Management of Colorectal Hepatic Metastases
Pacific Coast Surgical Association    
2000   Senior Author – Presentation Lymphatic mapping and focused analysis of sentinel lymph nodes upstages gastrointestinal neoplasms.
2002   Senior Author - Presentation Anti-GM2 IgM response is the only predictor of survival in stage II colorectal cancer.
2007   Senior Author-Presentation Angiogenesis markers in early colorectal cancer predict lymph node metastases.
2008   Senior Author – Presentation Primary colorectal tumor characteristics as predictors of occult nodal metastasis in a prospective multicenter trial.
2011   Discussant Colonoscopic tattoing increases lymph node yield in colon cancer
Pancreas Club    
1988   Presented – Digestive Disease Week CCK receptor blockade in two models of experimental pancreatitis not mediated via CCK receptors.
2005   Contributing Author – Oral presentation Detection of KRAS DNA mutation in the surgical margins of resected pancreatic adenocarcinoma correlates with survival.
Roswell Park Cancer Center, Grand Rounds    
2005   Invited Lecturer Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation
San Diego Society of General Surgeons    
2003   Invited Lecturer Impact of lymphatic mapping and sentinel lymph node analysis on the new TNM staging.
Society of American GI Endoscopic Surgeons (SAGES)    
2000   Senior Author – Presentation Diagnostic laparoscopy and laparoscopic ultrasonography optimize staging and resectability of intra-abdominal tumors.
2000   Senior Author - Presentation Laparoscopic ultrasound and radiofrequency ablation of nonresectable hepatic malignancies: A phase II trial.
2000   Senior Author - Presentation Colonoscopic lymphatic mapping in laparoscopic colectomy for cancer.
2000   Faculty Lecturer – Postgraduate Course I Sentinel node technique for colorectal neoplasms.
Society for Surgery of Alimentary Tract    
1988   Presented-Digestive Disease Week Does VIP mediate the pathophysiology of bowel obstruction?
1993   Presented PYY augments postprandial small intestinal absorption in vivo.
1997   Presented Human pancreatic carcinoma growth and invasion is regulated by C-MET and Interleukin 4 receptor gene expression.
2000   Senior Author – Poster Presentation Repeat hepatic cryotherapy for metastatic colorectal cancer.
2001   Senior Author - Poster Presentation Diagnostic laparoscopy and laparoscopic ultrasonography are essential for staging intraabdominal neoplasms.
2001   Senior Author - Presentation One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases.
2002   Senior Author - Presentation Lymphatic mapping combining blue dye with intraoperative lymphoscintigraphy improves detection of micrometastases in early colorectal cancer.
2002   Second Author - Presentation Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: A novel treatment strategy.
Society of Surgical Oncology    
1997   Senior Author – Presentation Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations & complications.
1997   Presented Cryosurgery ameliorates unresectable hepatic neuroendocrine metastases.
1998   Presented Cellular immune response to CancerVax in patients receiving active immunotherapy for metastatic cancers.
1998   Poster Presentation Survival and the humoral immune response to TA90 in patients receiving active immunotherapy with CancerVax for metastatic cancers.
1998   Presented Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
1999   Presented Survival is correlated with humoral response to TA-90 in patients receiving CancerVax for metastatic cancers.
1999   Poster Presentation Radiofrequency ablation and intraoperative ultrasound – a novel approach for management of unresectable hepatic malignancies.
1999   Poster Presentation TA-90 – A new marker for colon cancer.
2000   Senior Author-Poster Presentation Designing a strategy for the care of children with melanoma.
2000   Senior Author – Presentation Validation of lymphatic mapping in colorectal carcinoma: In-vivo, ex-vivo and laparoscopic techniques.
2000   Senior Author – Presentation Radiofrequency ablation of 174 unresectable hepatic tumors: indications, limitations and complications.
2000   Invited Presenter RT-PCR techniques to detect micrometastases in lymph nodes.
2000   2nd Author – Presentation Accuracy of ultrastaging of colorectal cancer by exclusive examination of sentinel lymph nodes: A prospective study.
2001   Senior Author – Poster Presentation Cryosurgical ablation of hepatic colorectal carcinoma metastases induces autoimmunization with tumor specific antibodies.
2001   Senior Author - Presentation Improved survival in refractory stage IV colorectal cancer is associated with a specific immune response to TA90.
2001   Senior Author - Presentation The results of hepatic cytoreduction plus regional and systemic chemotherapy in 185 patients with unresectable colorectal cancer metastasis.
2002   Co-Author - Presentation Modulators of ceramide metabolism enhance irinotecan-mediated apoptosis of colon cancer cells by a p53-independent process.
2002   Senior Author - Presentation Radiofrequency ablation in 406 complex unresectable liver tumors: Lessons learned.
2002   Panelist - Contemporary Surgery Symposium Ablative therapies for liver cancer.
2002   Presented – “Meet the Professor” Breakfast Sentinel lymph node biopsy and colon cancer: Breakthrough vs. fad.
2003   Presented – “Meet the Professor” Breakfast Micrometastases in colon cancer: Perception vs. reality.
2003   Invited Lecturer Tailoring treatment to improve survival in hepatic colorectal metastases.
2005   Presented – “Meet the Professor” Breakfast Ablation of Liver Metastasis, Minimally Invasive but Should It Replace Resection?
2006   Invited Lecturer Indications and Evidence for Radiofrequency Ablation of Liver Tumors
2007   Invited Lecturer Treatment of Colorectal Liver Metastases What are the limits? What are the goals?
2008   Invited Lecturer Multidisciplinary approach to Neuroendocrine Tumors
2009   Invited Lecturer Advances in the Staging of Gastrointestinal Neoplasms
Society of University Surgeons    
1993   Presented Effects of luminal hexoses on jejunal absorption.
Southern California Society of Colon and Rectal Surgeons;    
2005   Invited Lecturer Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation
Southwestern Surgical Congress    
2007   Senior Author-Oral Presentation Management of T2 Gallbladder Cancer: Are Practice Patterns Consistent With National Recommendations
2011   Senior Author- Oral Presentation Metastatic Hepatoblastoma. Resection of the primary lesion results in improved survival
Surgical Forum    
1989   Presented cAMP mediated release of PYY from the isolated perfused colon: Evidence for negative feedback modulation of colonic secretion.
1993   Presented PYY gene expression is an early adaptive response to massive small bowel resection
1993   Presented Translational control of meal-induced absorption.
Tripartite Surgical Meeting    
1988   Presented New specific CCK receptor antagonist ameliorates surgically induced pancreatitis both pre and post insult.
University of California Irvine Grand Rounds    
2005   Invited Lecturer Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation
University of California Los Angeles    
1997   Visiting Lecturer Physiology and bioactivity of gastrointestinal hormones.
University of California San Francisco- International Symposium on Cancer Metastasis and the Lymphovascular System    
2005   Invited Lecturer Lymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation
2007   Invited Lecturer GI cancer and the lymphatic system: Patterns of micrometastasis and lymphatic mapping with clinical outcome
2007   Senior Author-Poster Presentation Thrombospondin; protective in preventing lymphatic metastases in colon cancer.
University of Minnesota    
1998   Participant Hepatic, Biliary & Pancreatic Surgery.
University of Nebraska    
1997   Visiting Lecturer Management of unresectable liver tumors.
University of Southern California Grand Rounds    
2004   Invited Lecturer Challenging the therapeutic equation in gastrointestinal tumors
University of Sydney    
1998   Visiting Lecturer - Graham Coupland Lecture Universal application of lymphatic mapping and sentinel node biopsy in solid neoplasms.
University of the Witwatersrand Medical Grand Rounds    
1987   Visiting Lecturer Potential therapeutic role of CCK receptor antagonists in pancreatic disease.
University of Cape Town Department of Chemical Pathology    
1987   Visiting Lecturer Role of CCK in the pathogenesis of acute pancreatitis.
Valley Lab Cool-Tip Liver RFA Symposium – Denver    
2004   Invited Lecturer Thermal Ablation of Hepatic Colorectal Metastases
Valley Lab Cool-Tip Liver RFA Symposium – La Jolla    
2005   Invited Lecturer Thermal Ablation of Hepatic Colorectal Metastases
Waterford Surgical Club – Waterford, Ireland    
2005   Invited Lecturer Thermal Ablation of Colorectal Liver Metastases: Minimally Invasive but Should it Replace Resection?
2005   Invited LecturerLymphatic Mapping in Colon Cancer: Challenging the Therapeutic Equation.
West Hawaii Cancer Symposium    
2001   Invited Lecturer Local/Regional approaches for hepatic tumors –What are the indications?
2001   Invited Lecturer Resected rectal cancer – Is adjuvant therapy still appropriate?
2002   Invited Lecturer Advanced colon cancer: Is cure possible?
2002   Invited Lecturer Adjuvant and palliative treatment of hepatic colorectal metastases: Integrating therapeutic options.
Western Surgical Association    
1999   Presented Cryosurgery and radiofrequency ablation of unresectable hepatic malignancies: A proposed algorithm.
2001   Presented Molecular profiling of early colon cancer predicts micrometastases.
2004   Discussant GIST tumors express RAS oncogene: A potential role for diagnosis and treatment.
2005   Oral Presentation Prospective multicenter trial of staging adequacy in colon cancer: Preliminary results.
2005   Senior Author – Oral presentation Long term survival with 521 complex unresectable liver tumors after radiofrequency ablation.
2006   Senior Author-Oral Presentation The Role of Repeat Hepatectomy in the Mulitmodal Treatment of Hepatic Colorectal Metastases
2012   2012 Oral Presentation The impact of age on quality measure adherence in colon cancer.
World Congress of International Society for Digestive Surgery    
2004   Invited Lecturer Dual-agent mapping of the sentinel node in colorectal cancer
2004   Invited Lecturer Navigating the sentinel node technique across cancers and continents
World Congress of Surgery    
1999   Presented Prognostic factors and the role of chemotherapy in 153 patients undergoing cryosurgery for unresectable colorectal metastases.
   
Copyright © 2013 Corigroup.org. All Right Reserved.